By-passing the nonsense mutation in the 4CV mouse model of muscular dystrophy by induced exon skipping

Journal of Gene Medicine

Volumn 11, Issue 1, 2009, Pages 46-56

  Mitrpant, Chalermchai ^a,b   Fletcher, Sue ^a   Iversen, Patrick L ^c   Wilton, Steve D ^a  

^a UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^b MAHIDOL UNIVERSITY   (Thailand)

^c AVI BIOPHARMA INC   (United States)

Author keywords

Antisense oligomer; B6Ros.Cg Dmdmdx 4Cv J (4CV) mouse; Duchenne muscular dystrophy; Exon skipping; Morpholino

Indexed keywords

2' O METHYL MODIFIED PHOSPHOROTHIOATE OLIGOMER; CELL PENETRATING PEPTIDE; DYSTROPHIN; MESSENGER RNA; OLIGOMER; PHOSPHORODIAMIDATE MORPHOLINO OLIGOMER; UNCLASSIFIED DRUG; ANTISENSE OLIGONUCLEOTIDE; MORPHOLINE DERIVATIVE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DNA BASE COMPOSITION; EXON; EXON SKIPPING; GENE TARGETING; GENETIC TRANSFECTION; IN VIVO STUDY; MOUSE; MUSCULAR DYSTROPHY; MYOBLAST; NONHUMAN; NONSENSE MUTATION; NUCLEOTIDE SEQUENCE; OPEN READING FRAME; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RNA TRANSCRIPTION; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE; ANIMAL; ANIMAL MUSCULAR DYSTROPHY; CHEMISTRY; GENETICS; INTRAMUSCULAR DRUG ADMINISTRATION; STOP CODON;

ANIMALS; CODON, NONSENSE; DYSTROPHIN; EXONS; INJECTIONS, INTRAMUSCULAR; MICE; MICE, INBRED MDX; MODELS, ANIMAL; MORPHOLINES; MUSCULAR DYSTROPHY, ANIMAL; OLIGONUCLEOTIDES, ANTISENSE;

EID: 59449107366     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.1265     Document Type: Article

References (46)

1. Blake DJ, Weir A, Newey SE, et al. Function and genetics of dystrophin and dystrophin-related proteins in muscle. Physiol Rev 2002; 82: 291-329.
2. Emery AE. Muscular dystrophy into the new millennium. Neuromuscul Disord 2002; 12: 343-349.
3. Emery AE. The muscular dystrophies. Lancet 2002; 359: 687-695.
4. Yan J, Feng J, Buzin CH, et al. Three-tiered noninvasive diagnosis in 96% of patients with Duchenne muscular dystrophy (DMD). Hum Mutat 2004; 23: 203-204.
5. White SJ, Aartsma-Rus A, Flanigan KM, et al. Duplications in the DMD gene. Hum Mutat 2006; 27: 938-945.
6. Deburgrave N, Daoud F, Llense S, et al. Protein- and mRNA-based phenotype-genotype correlations in DMD/BMD with point mutations and molecular basis for BMD with nonsense and frameshift mutations in the DMD gene. Hum Mutat 2007; 28: 183-195.
7. Ashton EJ, Yau SC, Deans ZC, et al. Simultaneous mutation scanning for gross deletions, duplications and point mutations in the DMD gene. Eur J Hum Genet 2008; 16: 53-61.
8. Tuffery-Giraud S, Chambert S, Demaille J, et al. Point mutations in the dystrophin gene: evidence for frequent use of cryptic splice sites as a result of splicing defects. Hum Mutat 1999; 14: 359-368.
9. Bosone I, Bortolotto S, Mongini T, et al. Late onset and very mild course of Xp21 Becker type muscular dystrophy. Clin Neuropathol 2001; 20: 196-199.
10. Heald A, Anderson LV, Bushby KM, et al. Becker muscular dystrophy with onset after 60 years. Neurology 1994; 44: 2388-2390.
11. Jennekens FG, ten Kate LP, de Visser M, et al. Diagnostic criteria for Duchenne and Becker muscular dystrophy and myotonic dystrophy. Neuromuscul Disord 1991; 1: 389-391.
12. Prior TW, Bartolo C, Papp AC, et al. Nonsense mutations in a Becker muscular dystrophy and an intermediate patient. Hum Mutat 1996; 7: 72-75.
13. Dunckley MG, Manoharan M, Villiet P, et al. Modification of splicing in the dystrophin gene in cultured Mdx muscle cells by antisense oligoribonucleotides. Hum Mol Genet 1998; 7: 1083-1090.
14. Wilton SD, Lloyd F, Carville K, et al. Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 1999; 9: 330-338.
15. Graham IR, Hill VJ, Manoharan M, et al. Towards a therapeutic inhibition of dystrophin exon 23 splicing in mdx mouse muscle induced by antisense oligoribonucleotides (splicomers): target sequence optimisation using oligonucleotide arrays. J Gene Med 2004; 6: 1149-1158.
16. Sirsi SR, Williams JH, Lutz GJ. Poly (ethylene imine)-poly (ethylene glycol) copolymers facilitate efficient delivery of antisense oligonucleotides to nuclei of mature muscle cells of mdx mice. Hum Gene Ther 2005; 16: 1307-1317.
17. Gebski BL, Mann CJ, Fletcher S, et al. Morpholino antisense oligonucleotide induced dystrophin exon 23 skipping in mdx mouse muscle. Hum Mol Genet 2003; 12: 1801-1811.
18. Mann CJ, Honeyman K, McClorey G, et al. Improved antisense oligonucleotide induced exon skipping in the mdx mouse model of muscular dystrophy. J Gene Med 2002; 4: 644-654.
19. Alter J, Lou F, Rabinowitz A, et al. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology. Nat Med 2006; 12: 175-177.
20. Fletcher S, Honeyman K, Fall AM, et al. Morpholino oligomer mediated exon skipping averts the onset of dystrophic pathology in the mdx mouse. Mol Ther 2007; 15: 1587-1592.
21. Fletcher S, Honeyman K, Fall AM, et al. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide. J Gene Med 2006; 8: 207-216.
22. Mitrpant C, Fletcher S, Wilton SD. Personalised genetic intervention for Duchenne muscular dystrophy: Antisense oligomers and exon skipping. Curr Mol Pharm 2008.
23. Foster K, Foster H, Dickson JG. Gene therapy progress and prospects: Duchenne muscular dystrophy. Gene Ther 2006; 13: 1677-1685.
24. Odom GL, Gregorevic P, Chamberlain JS. Viral-mediated gene therapy for the muscular dystrophies: successes, limitations and recent advances. Biochim Biophys Acta 2007; 1772: 243-262.
25. Welch EM, Barton ER, Zhuo J, et al. PTC124 targets genetic disorders caused by nonsense mutations. Nature 2007; 447: 87-91.
26. Chapman VM, Miller DR, Armstrong D, et al. Recovery of induced mutations for X chromosome-linked muscular dystrophy in mice. Proc Natl Acad Sci USA 1989; 86: 1292-1296.
27. Deas TS, Binduga-Gajewska I, Tilgner M, et al. Inhibition of flavivirus infections by antisense oligomers specifically suppressing viral translation and RNA replication. J Virol 2005; 79: 4599-4609.
28. Yuan J, Stein DA, Lim T, et al. Inhibition of coxsackievirus B3 in cell cultures and in mice by peptide-conjugated morpholino oligomers targeting the internal ribosome entry site. J Virol 2006; 80: 11510-11519.
29. Errington SJ, Mann CJ, Fletcher S, et al. Target selection for antisense oligonucleotide induced exon skipping in the dystrophin gene. J Gene Med 2003; 5: 518-527.
30. Rando TA, Blau HM. Primary mouse myoblast purification, characterization, and transplantation for cell-mediated gene therapy. J Cell Biol 1994; 125: 1275-1287.
31. Wilton SD, Lim L, Dye D, et al. Bandstab: a PCR-based alternative to cloning PCR products. Biotechniques 1997; 22: 642-645.
32. Cartegni L, Wang J, Zhu Z, et al. ESEfinder: a web resource to identify exonic splicing enhancers. Nucleic Acids Res 2003; 31: 3568-3571.
33. Smith PJ, Zhang C, Wang J, et al. An increased specificity score matrix for the prediction of SF2/ASF-specific exonic splicing enhancers. Hum Mol Genet 2006; 15: 2490-2508.
34. Morgan JE, Beauchamp JR, Pagel CN, et al. Myogenic cell lines derived from transgenic mice carrying a thermolabile T antigen: a model system for the derivation of tissue-specific and mutation-specific cell lines. Dev Biol 1994; 162: 486-498.
35. McClorey G, Moulton HM, Iversen PL, et al. Antisense oligonucleotide-induced exon skipping restores dystrophin expression in vitro in a canine model of DMD. Gene Ther 2006; 13: 1373-1381.
36. Mann CJ, Honeyman K, Cheng AJ, et al. Antisense-induced exon skipping and synthesis of dystrophin in the mdx mouse. Proc Natl Acad Sci USA 2001; 98: 42-47.
37. Lu QL, Mann CJ, Lou F, et al. Functional amounts of dystrophin produced by skipping the mutated exon in the mdx dystrophic mouse. Nat Med 2003; 9: 1009-1014.
38. Den Dunnen JT, Grootscholten PM, Bakker E, et al. Topography of the Duchenne muscular dystrophy (DMD) gene: FIGE and cDNA analysis of 194 cases reveals 115 deletions and 13 duplications. Am J Hum Genet 1989; 45: 835-847.
39. Wilton SD, Fall AM, Harding PL, et al. Antisense oligonucleotide-induced exon skipping across the human dystrophin gene transcript. Mol Ther 2007; 15: 1288-1296.
40. Arechavala-Gomeza V, Graham IR, Popplewell LJ, et al. Comparative analysis of antisense oligonucleotide sequences for targeted skipping of exon 51 during dystrophin pre-mRNA splicing in human muscle. Hum Gene Ther 2007; 18: 798-810.
41. Harding PL, Fall AM, Honeyman K, et al. The influence of antisense oligonucleotide length on dystrophin exon skipping. Mol Ther 2007; 15: 157-166.
42. McKay RA, Miraglia LJ, Cummins LL, et al. Characterization of a potent and specific class of antisense oligonucleotide inhibitor of human protein kinase C-alpha expression. J Biol Chem 1999; 274: 1715-1722.
43. Gebski BL, Errington SJ, Johnsen RD, et al. Terminal antisense oligonucleotide modifications can enhance induced exon skipping. Neuromuscul Disord 2005; 15: 622-629.
44. McClorey G, Fall AM, Moulton HM, et al. Induced exon skipping in human muscle explants. Neuromusc Disorders 2006; 16: 583-590.
45. Fall AM, Johnsen R, Honeyman K, et al. Induction of revertant fibres in the mdx mouse using antisense oligonucleotides. Genet Vaccines Ther 2006; 4: 3.
46. Adams AM, Harding PL, Iversen PL, et al. Antisense oligonucleotide induced exon skipping and the dystrophin gene transcript: cocktails and chemistries. BMC Mol Biol 2007; 8: 57.